EAACI 2017: The future of urticaria – advances in CSU research

 

  • Date of activity

    22nd March 2018 – 22nd March 2019

    Course overview

    This educational activity has been designed for healthcare professionals who are involved in the care of patients with chronic spontaneous urticaria (CSU).

    This educational activity is based on presentations given at the epgonline.org-sponsored symposium ‘The future of urticaria – advances in CSU research’ at the European Academy of Allergy and Clinical Immunology (EAACI) annual meeting in June 2017.

    This CME was supported by an educational grant from Novartis, who were given the opportunity to review the content for medical accuracy only. 

    This course consists of 4 modules that include video clips taken from expert presentations interspersed with quiz and evaluation questions. To claim CME credit you must complete all presentations and achieve a score of 70% in the final assessment.

    Presentation Expert

    Under the skin of CSU - diagnostic and prognostic biomarkers in urticaria

    Professor Martin Metz

    Keeping it real: a look at the latest real-world data in CSU management

    Dr Alexander Marsland

    Efficacy of optimised retreatment with omalizumab in CIU/CSU patients

    Professor Gordon Sussman

    Looking beyond CSU: A recent round-up of recent research

    Professor Marcus Maurer

    Learning objectives

    On completion of the activity, participants will understand:

    • The continuing unmet needs in chronic spontaneous urticaria (CSU)
    • The progress made in identifying and managing CSU patients
    • The latest research in therapy areas beyond CSU that may benefit from our increased pathophysiological understanding


    Faculty

    Professor Martin Metz

    Professor Martin Metz
    Professor of Dermatology at the Charité – Universitätsmedizin, Berlin, Germany. Professor Metz also holds senior positions within the Pruritus working groups of the German Society for Dermatology (DDG) and the German Society for Dermatological Research (ADF).

    Disclosures: Speaker and/or consultant for Bayer, Beiersdorf, Jenapharm, Menlo Therapeutics, Merz, Moxie, Nerre, Novartis, Pierre Fabre, Roche, Sanofi and Shire.

    Dr Alexander Marsland

    Dr Alexander Marsland
    Consultant dermatologist at Salford Royal  Foundation Trust, Salford, UK. Dr Marsland is an urticaria representative for the UK North West Allergy and Clinical Immunology Network and an advisor for the National Institute for Health Research National Horizon Scanning Centre.

    Disclosures: Consultancies - Novartis, Galderma, UCB Pharma. Speaker fees and travel assistance - Novartis, Galderma, GSK, MEDA.

    Professor Gordon Sussman

    Professor Gordon Sussman
    Professor of Medicine and Division Director, Adult Clinical Immunology and Allergy, University of Toronto, Canada. Also President of The Allergy Asthma Immunology Society of Ontario, Canada and has been actively involved in the revision of the EAACI/GA2LEN/EDF/WAO Guideline for Urticaria.

    Disclosures: Speaker and consultanat for Novartis and Aralez. Consultant for Merck, Pfizer, DBV Technologies, Aimmune Pharmaceuticals, GSK, Kendrion, GreenCross, Genentech, Stallergenes, CSL Behring, BioCryst, Shire and AstraZeneca.

    Professor Marcus Maurer

    Professor Marcus Maurer
    Professor of Dermatology and Allergy at the Charité – Universitätsmedizin, Berlin, Germany. Professor Maurer’s clinical interests are in urticaria, mastocytosis, angioedema, pruritus, skin infections and allergic diseases.

    Disclosures: Research funding - Deutsche Forschungsgemeinschaft (DFG), EU (FP7, COST), European Centre of Allergy Research Foundation (ECARF), Urticaria Network e.V. (UNEV), Bayer, Leo, Novartis, Reimser and Uriach. Speaker and/or consultant - Almirall Hermal, Bayer, BioCryst, Dyax, FAES, Genentech, Leo, Merckle Recordarti, Moxie, MSD, Novartis, Riemser, Sanofi Aventis, Shire, Takeda, UCB and Uriach.

    Support

    This activity is supported by funding from Novartis Pharma AG.

    Accreditation

    ‘EAACI 2017: The future of urticaria – advances in CSU research’ made by EPG Health, is awarded 1 European CME credit (ECMEC).

    Each medical specialist should claim only those credits that he/she actually spent in the educational activity. The EACCME is an institution of the European Union of Medical Specialists (UEMS). Only those e-learning materials that are displayed on the UEMS-EACCME website have formally been accredited.

    Additional information

    System requirements

    PC Mac

    Microsoft Windows 2000 or above.
    Internet Explorer (v8 or greater), Chrome, Safari or Firefox
    Adobe Acrobat Reader*

    MAC OS 10.2.8
    Safari or Chrome
    Adobe Acrobat Reader*
    Internet Explorer is not supported on the Macintosh.

    *Required to view printable (PDF) version of the completion certificate.

    Fee information

    There is no fee for this educational activity.

Iniciar sesión/Registrarse Ampliar Reducir